Johnson & Johnson (NYSE:JNJ) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In.
Following a strong positive quarter, the company witnesses a rise in price target and announces new data on its pill.
Johnson & Johnson reported an EPS of $2.77 for the second quarter of 2025 on July 16, 2025, successfully surpassing the consensus analyst estimate of $2.68. Similarly, the company’s revenue of $23.74 billion for the quarter exceeded analyst expectations of $22.85 billion, signaling a good performance amid a complex economic environment. The company’s board has also declared a quarterly cash dividend of $1.30 per share, representing a 63rd consecutive annual dividend increase and a growth from the previous quarter’s rate of $1.24 per share.
Following the strong quarter, JP Morgan raised the stock’s price target from $185 to $195 while keeping a Neutral rating. Additionally, the company announced new data from the Phase 3 Iconic-Advance 1 and 2 studies on icotrokinra, which hints at the superiority of the pill to deucravacitinib and placebo in treating moderate-to-severe plaque psoriasis.
Holding on to this positive outlook, Johnson & Johnson offers a dividend yield of 2.95% attracting investors looking for a stable income.
The American multinational corporation, Johnson & Johnson, was founded in 1886. Headquartered in New Jersey, the company is a global leader in the healthcare industry, specializing in the development of pharmaceuticals and consumer health products.
READ NEXT: 11 Best Performing IPOs in the Last 2 Years and 12 Jim Cramer Stock Picks this Week
Disclosure. None.
